Intel stock spikes after report of possible US government stake
Investing.com - H.C. Wainwright lowered its price target on Assertio Therapeutics (NASDAQ:ASRT) to $3.00 from $3.50 on Tuesday while maintaining a Buy rating following the company’s second-quarter financial results. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $1.50 to $3.50, suggesting significant upside potential from the current price of $0.72.
Assertio reported revenue of $29.2 million for the second quarter of 2025, exceeding the research firm’s original forecast of $28 million. Despite the revenue beat, the company narrowed its 2025 net product sales guidance to $108-118 million from the previous range of $108-123 million. InvestingPro analysis shows the company trading at a low revenue valuation multiple, with additional metrics and insights available in the Pro Research Report.
The pharmaceutical company posted a net loss of $0.17 per share in the second quarter, wider than H.C. Wainwright’s original forecast for a net loss of $0.10 per share. The research firm now projects a full-year 2025 net loss of $0.44 per share, compared to its previous estimate of a $0.27 per share loss.
H.C. Wainwright also reduced its full-year 2026 revenue estimate to $115 million from $135.6 million, citing "modulated expectations" for Assertio’s legacy products and the cessation of commercial activities for OTREXUP (methotrexate).
Assertio ended the second quarter with $98.2 million in cash, cash equivalents, and marketable securities, according to the research note. InvestingPro data confirms the company holds more cash than debt on its balance sheet, maintaining a healthy current ratio of 1.66.
In other recent news, Assertio Therapeutics Inc. reported its second-quarter 2025 earnings, outperforming analyst expectations. The company achieved an earnings per share (EPS) of $0.02, defying forecasts that projected a loss of $0.08, resulting in a surprising 125% beat. Revenue figures also exceeded predictions, reaching $28.8 million compared to the anticipated $27.87 million. These results highlight Assertio Therapeutics’ ability to surpass market expectations. Despite the positive earnings, the stock saw a decline in aftermarket trading, though this movement is not detailed further. These developments reflect recent performance and provide insight into the company’s current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.